Perrigo sought tentative FDA approval for Soolantra cream, 1%

Perrigo Company declared having sought tentative U.S FDA approval for the generic version of Soolantra cream,1%. Soolantra cream implied for the treatment of inflammatory lesions of rosacea. According to the IMS Health,  Annual market sales for the last 12 months were approximately $120 million.

Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, “This is the Rx team’s fifth generic product approval this month. This tentative approval further illustrates our commitment to advancing our new product pipeline and providing savings to patients and healthcare systems.”